<DOC>
	<DOCNO>NCT01882374</DOCNO>
	<brief_summary>The purpose study evaluate efficacy TXA127 reduce incidence ( Grade II-IV ) acute Graft-vs.-Host Disease ( aGVHD ) adult subject undergo double umbilical cord blood transplantation ( UCBT ) . The study also evaluate effect TXA127 incidence , severity duration mucositis ; neutrophil engraftment platelet recovery ; platelet transfusion requirement ; immune reconstitution ; duration corticosteroid use . TXA127 show well tolerated patient appear induce rapid production neutrophil platelet bloodstream , well increase immune system component . TXA127 also show reduce severity chemotherapy-induced mucositis .</brief_summary>
	<brief_title>Efficacy Study TXA127 Reduce Acute Graft-vs-Host Disease Subjects Undergoing Double Umbilical Cord Blood Transplantation</brief_title>
	<detailed_description>Cord blood ( CB ) hematopoietic stem cell source multiple advantage . Cord blood normally discard birth easily collect store . Availability numerous CB bank result genetically diverse CB unit include non-Caucasians . Once suitable CB unit locate , confirmatory type quickly perform donor unit ship transplant center . Furthermore , CB graft result low incidence graft-versus-host disease ( GVHD ) , one two antigen-mismatches may acceptable transplantation . Despite advantage , CB significant drawback : number hematopoietic stem cell obtain unit CB significantly low bone marrow ( BM ) peripheral blood stem cell ( PBSC ) harvest . The number stem cell increase transplant two cord blood unit , however incidence GVHD increase patient receive two CB unit compare patient receive one unit . Another issue population mucositis , result myeloablative conditioning give prior transplant , debilitate patient . TXA127 pharmaceutically-formulated angiotensin 1-7 , non-hypertensive derivative angiotensin II ( contain 8th amino acid confer receptor bind blood pressure receptor ) . TXA127 multilineage effect hematopoietic progenitor vitro vivo . The hematopoietic property demonstrate preclinical clinical study support investigation TXA127 reduce incidence acute GVHD ( aGVHD ) mucositis patient population .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<criteria>Provided write informed consent . ≥18 year age . Meet institutional standard criterion double UCB transplantation Myeloablative conditioning regimen Histologically confirm diagnosis hematologic malignancy . Life expectancy ≥4 month . Female subject capable reproduction ( define subject start menses ) must agree follow : 1 ) Use effective oral IM contraceptive method course study 2 month follow last administration Investigational Product ; 2 ) must negative pregnancy test result within 7 day prior first Investigational Product dose . Uncontrolled infection time transplant . Pregnant breastfeeding . Known seropositive HIV HTLV1 . Active CNS disease time study enrollment . Treatment investigational agent within 30 day anticipate administration first dose Investigational Product . Current alcohol use , illicit drug use condition ( e.g. , psychiatric disorder ) , opinion Investigator , may interfere subject 's ability comply study requirement visit schedule . Any comorbid condition , view Principal Investigators , render subject high risk treatment complication regimenrelated morbidity/mortality . Prophylactic treatment palifermin mucositis . Subjects know sensitivity Investigational Product component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Double Umbilical Cord Blood Transplantation</keyword>
	<keyword>Acute Graft versus Host Disease</keyword>
	<keyword>Neutrophil Engraftment</keyword>
	<keyword>Platelet Recovery</keyword>
	<keyword>Immune Reconstitution</keyword>
	<keyword>Mucositis</keyword>
</DOC>